White House pushes FDA-strengthening legislation to blunt impact of drug shortages
The White House also asked the Justice Department to work with FDA to make sure the shortages aren't leading to price gouging.
"The shortage of prescription drugs drives up costs, leaves consumers vulnerable to price gouging, and threatens our health and safety," President Obama said in a statement. "This is a problem we can't wait to fix. That's why today I am directing my administration to take steps to protect consumers from drug shortages, and I'm committed to working with Congress and industry to keep tackling this problem going forward."
Health and Human Services Secretary Kathleen Sebelius admitted that the order didn't have much clout and urged Congress to hurry up with the legislation. "We don't have a lot of teeth in terms of enforcement," she told reporters on a conference call. "We were hoping that by this point, Congress would have acted."
Joint bills to give FDA more clout to prevent drug shortages have been introduced: S. 296 sponsored by Sen. Amy Klobuchar, D-Minn., and H.R. 2245 by Rep. Diana DeGette, D-Colo. Both have bipartisan support and no real opposition.
The executive order directs FDA to broaden reporting of potential shortages of certain prescription drugs and to speed up work to prevent or respond to shortages. FDA Commissioner Dr. Peggy Hamburg said even a little more notice can help the agency ensure that hospitals and clinics that need the drugs the most get them.
Hamburg said the order would raise the number of FDA staff working directly on the issue from five to 11.
"While FDA successfully prevented 137 drug shortages between Jan. 1, 2010 and Sept. 26, 2011, prescription drug shortages continue to threaten the health and safety of the American people," the White House said in a statement.
"These shortages could lead to price gouging, which has raised serious concerns. For example, the ranking member of the House Committee on Oversight and Government Reforms, when announcing his investigation into so-called gray markets, expressed concerns about a report that a leukemia drug whose typical contract price is about $12 per vial was being sold at $990 per vial - 80 times higher," the White House statement said.